Exome Asset Management LLC Acquires Shares of 116,623 AnaptysBio, Inc. $ANAB

Key Points

• Exome Asset Management LLC purchased 116,623 shares of AnaptysBio, Inc. valued at approximately $2,168,000, making it the fund's 25th largest holding.
• Analysts have given AnaptysBio a consensus rating of "Moderate Buy" with an average target price of $46.13, with several brokerages recently increasing their target prices.
• Insider activity includes Director Hollings Renton selling 20,925 shares for a total of approximately $493,202, resulting in an 80.82% decrease in their position.

Exome Asset Management LLC bought a new position in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 116,623 shares of the biotechnology company's stock, valued at approximately $2,168,000. AnaptysBio comprises about 1.8% of Exome Asset Management LLC's portfolio, making the stock its 25th largest position. Exome Asset Management LLC owned 0.40% of AnaptysBio as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently modified their holdings of ANAB. First Light Asset Management LLC raised its stake in shares of AnaptysBio by 433.3% in the first quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company's stock worth $86,139,000 after acquiring an additional 3,764,720 shares during the last quarter. Sanofi acquired a new stake in shares of AnaptysBio during the 4th quarter worth approximately $10,882,000. Soleus Capital Management L.P. acquired a new stake in shares of AnaptysBio during the 4th quarter worth approximately $5,481,000. Caption Management LLC grew its position in shares of AnaptysBio by 106.3% during the 1st quarter. Caption Management LLC now owns 23,376 shares of the biotechnology company's stock worth $435,000 after buying an additional 394,634 shares during the period. Finally, 683 Capital Management LLC acquired a new stake in shares of AnaptysBio during the 1st quarter worth approximately $3,637,000.

AnaptysBio Price Performance

NASDAQ ANAB traded up $0.20 on Friday, hitting $23.40. 472,652 shares of the stock were exchanged, compared to its average volume of 733,624. The business's fifty day moving average is $23.08 and its 200 day moving average is $21.02. AnaptysBio, Inc. has a 52 week low of $12.21 and a 52 week high of $40.70. The company has a market capitalization of $655.13 million, a PE ratio of -5.22 and a beta of -0.19.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.50) by $0.16. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. The firm had revenue of $22.26 million for the quarter, compared to analyst estimates of $11.55 million. Analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

Insider Transactions at AnaptysBio

In other AnaptysBio news, Director Hollings Renton sold 20,925 shares of the company's stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total transaction of $493,202.25. Following the sale, the director directly owned 4,965 shares of the company's stock, valued at approximately $117,025.05. This represents a 80.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 33.50% of the company's stock.

Analysts Set New Price Targets

ANAB has been the subject of several analyst reports. Wedbush lifted their price target on shares of AnaptysBio from $40.00 to $45.00 and gave the stock an "outperform" rating in a research report on Thursday, August 7th. JPMorgan Chase & Co. increased their target price on AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. UBS Group restated a "neutral" rating and set a $20.00 target price (up from $18.00) on shares of AnaptysBio in a research report on Tuesday, August 12th. Guggenheim reiterated a "buy" rating and issued a $90.00 price target (up from $54.00) on shares of AnaptysBio in a research report on Wednesday, May 28th. Finally, HC Wainwright raised shares of AnaptysBio from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $22.00 to $38.00 in a research note on Wednesday, June 4th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, AnaptysBio presently has a consensus rating of "Moderate Buy" and a consensus target price of $46.13.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.